Key result
AZD0837 demonstrated a favorable safety profile and similar bleeding rates compared to VKAs in a phase II study, supporting its progression to phase III trials.
Population
Patients with atrial fibrillation
Comparison
AZD0837 and other novel oral anticoagulants vs Vitamin K antagonists (VKAs)
Design
Editorial
Authors
Loading...
The direct thrombin inhibitor AZD0837 shows a promising safety profile without severe hepatotoxicity, though the need for monitoring novel anticoagulants remains an open question.
The direct thrombin inhibitor AZD0837 shows a promising safety profile without severe hepatotoxicity, though the need for monitoring novel anticoagulants remains an open question.
Steffel et al. (2009) conducted an editorial in Atrial fibrillation. AZD0837 vs. Vitamin K antagonists (VKAs) was evaluated. AZD0837 demonstrated a favorable safety profile and similar bleeding rates compared to VKAs in a phase II study, supporting its progression to phase III trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: